[February 20, 2018]

Venofer (poly-nuclear iron (III)-hydroxide in sucrose; Vifor/Luitpold Pharmaceuticals) Drug Analysis 2018 - ResearchAndMarkets.com

The "Drug Analysis: Venofer" drug pipelines has been added to ResearchAndMarkets.com's offering.

Venofer (poly-nuclear iron (III)-hydroxide in sucrose; Vifor/Luitpold Pharmaceuticals) is an iron maintenance treatment used to help elevate hemoglobin levels in patients with anemia in chronic kidney disease. It is administered intravenously and is dissociated into iron and sucrose once in circulation. The iron is transported via transferrin to erythroid precursor cells. Erythroid precursor cells incorporate the iron into hemoglobin as the cell matures into a red blood cell.

Key Topics Covered: /p>

Figure 1: Venofer for anemia in chronic kidney disease - SWOT analysis

Figure 2: Drug assessment summary of Venofer for anemia in chronic kidney disease

Figure 3: Drug assessment summary of Venofer for anemia in chronic kidney disease

Figure 4: Venofer sales for anemia in chronic kidney disease across the US, Japan, and five major EU markets, by country, 2015-24

List of Tables

Table 1: Venofer drug profile

Table 2: Venofer pivotal trial data in anemia in chronic kidney disease

Table 3: Venofer late-phase trial data in anemia in chronic kidney disease

Table 4: Venofer sales for anemia in chronic kidney disease across the US, Japan, and five major EU markets, by country ($m), 2015-24

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/m2th6p/venofer?w=4

View source version on businesswire.com: http://www.businesswire.com/news/home/20180220006335/en/

[ Back To TMCnet.com's Homepage ]